Downregulation of proapoptotic proteins Bax and Bcl-X(s) in p53 overexpressing hepatocellular carcinomas

Biochemical and Biophysical Research Communications

Volumn 273, Issue 1, 2000, Pages 54-61

  Beerheide, Walter ^a   Tan, Yee Joo ^a   Teng, Eileen ^a   Ting, Anthony E ^a   Jedpiyawongse, Adisorn ^b   Srivatanakul, Petcharin ^b  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b NATIONAL CANCER INSTITUTE   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P21; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; THAILAND;

EID: 0034709564     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2000.2891     Document Type: Article

References (53)

1. Srivatanakul P., Parkin D. M., Jiang Y. Z., Khlat M., Kao-Ian U. T., Sontipong S., Wild C. P. The role of infection by Opisthorchis viverini, hepatitis B virus and aflatoxin exposure in the etiology of liver cancer in Thailand. Cancer. 68:1991;2411-2417.
2. Srivatanakul P., Parkin D. M., Khlat M., Chenvidhya D., Hotiwan P., Insiripong S., L'Abbe K. A., Wild C. P. Liver cancer in Thailand. II. A case-control study of hepatocellular carcinoma. Int. J. Cancer. 48:1991;329-332.
3. Parkin, D. M, Muir, C. S, Whelan, S. L, Gao, Y. T, Ferlay, J, and, Powell, J. (Eds.), 1992, Cancer Incidence in Five Continents, Vol. VI, IARC Scientific Publications 120, International Agency for Research on Cancer, Lyon.
4. Vatanasapt V., Martin N., Sriplung H., Chindavijak K., Sontipong S., Sriamporn H., Parkin D. M., Ferlay J. Cancer incidence in Thailand, 1988-1991. Cancer Epidemiol. Biomarkers Prev. 4:1995;475-483.
5. Deerasamee, S, Martin, N, Sontipong, S, Sriamporn, H, Sriplung, P, Srivatanakul, P, Vatanasapt, V, Parkin, D. M, and, Ferlay, J. 1999, Cancer in Thailand, Vol. II, 1992, - 1994, IARC Technical Report No. 34, International Agency for Research on Cancer, Lyon.
6. Parkin D. M., Srivatanakul P., Khlat M., Chenvidhya D., Chotiwan P., Insiripong S., L'Abbe K. A., Wild C. P. Liver cancer in Thailand. I. A case-control study of cholangiocarcinoma. Int. J. Cancer. 48:1991;323-328.
7. Parkin D. M., Ohshima H., Srivatanakul P., Vatanasapt V. Cholangiocarcinoma: Epidemiology, mechanisms of carcinogenesis and prevention. Cancer Epidemiol. Biomarkers Prev. 2:1993;537-544.
8. Montesano R., Hainaut P., Wild C. P. Hepatocellular carcinoma: From gene to public health. J. Natl. Cancer Inst. 17:1997;1844-1851.
9. Bressac B., Kew M., Wands J., Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern. Nature (London). 350:1991;429-431.
10. Hsu I. C., Metcalf R. A., Sun T., Welsh J. A., Wang N. J., Harris C. C. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature (London). 350:1991;427-428.
11. 1 exposure in hepatocellular carcinoma patients from Thailand. Int. J. Cancer. 53:1993;51-55.
12. El-Deiry W. S. p21/p53, cellular growth control and genomic integrity. Curr. Topics Microbiol. Immunol. 227:1998;121-137.
13. Peng S. Y., Chou S. P., Hsu H. C. Association of downregulation of cyclin D1 and of overexpression of cyclin E with p53 mutation, high tumor grade and poor prognosis in hepatocellular carcinoma. J. Hepatol. 29:1998;281-289.
14. Haldar S., Negrini M., Monne M., Sabbioni S., Croce C. M. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 54:1994;2095-2057.
15. Miyashita T., Harigai M., Hanada M., Reed J. C. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 54:1994;3134-3135.
16. Miyashita T., Krajewski S., Krajewska M., Wang H. G., Lin H. K., Liebermann D. A., Hoffman B., Reed J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expressions in vitro and in vivo. Oncogene. 9:1994;1799-1805.
17. Selvakumaran M., Lin H. K., Miyashita T., Wang H. G., Krajewski S., Reed J. C., Hoffman B., Liebermann D. Immediate early up-regulation of bax expression by p53 but not TGFβ: A paradigm for distinct apoptotic pathways. Oncogene. 9:1994;1791-1798.
18. Kim N. W., Piatyszek M. A., Prowse K. R., Harley C. B., Wset M. D., Ho P. L. C., Coviello G. M., Wright W. E., Weintich S. L., Shay J. W. Specific association of human telomerase activity with immortal cells and cancer. Science. 266:1994;2011-2014.
19. Tahara H., Nakanishi T., Kitamoto M., Nakashio R., Shay J. W., Tahar E., Kajiyawa G., Ide T. Telomerase activity in human liver tissues: Comparison between chronic liver disease and hepatocellular carcinomas. Cancer Res. 55:1995;2734-2736.
20. Kirby G. M., Wolf C. R., Neal G. E., Judah D. J., Henderson C. J., Srivatanakul P., Wild C. P. In vitro. 12:1993;2613-2620.
21. Kaplanski C., Srivatanakul P., Wild C. P. Frequent rearrangements at minisatellite loci dis7 (1p33-35), d7s22 (7q36-ter) and d12s11 (12q24.3-ter) in hepatitis B virus-positive hepatocellular carcinomas from Thai patients. Int. J. Cancer. 72:1997;248-257.
22. Nagao K., Tomimatsu M., Enbo H., Hisatomi H., Hikiji K. J. Telomerase reverse transcriptase mRNA expression and telomerase activity in hepatocellular carcinoma. Gastroenterology. 34:1999;83-87.
23. Zhivotovsky B., Hanson K. P., Orrenius S. Back to the future: The role of cytochrome c in cell death. Cell Death Differ. 5:1998;459-460.
24. Kroemer G. The proto-oncogene BCL-2 and its role in regulating apoptosis. Nature Med. 6:1997;614-620.
25. Levine A. J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
26. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 253:1991;49-52.
27. Henkler F., Waseem N., Golding M. H. C., Alison M. R., Koshy R. Mutant p53 but not hepatitis B virus × protein is present in hepatitis B virus related human hepatocellular carcinoma. Cancer Res. 55:1995;6084-6091.
28. Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in the p53 tumor suppressor gene: Clues to cancer epidemiology and molecular pathogenesis. Cancer Res. 54:1994;4855-4878.
29. Harris C. C. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst. 88:1996;1442-1445.
30. Kubbutat M. H. G., Vousden K. H. Keeping an old friend under control: Regulation of p53 stability. Mol. Med. Today. 6:1998;250-256.
31. Ueda H., Ullrich S. J., Gangemi J. D., Kappel C. A., Ngo L., Feitelson M. A., Jay G. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat. Genet. 9:1995;41-47.
32. Feitelson M. A., Zhu M., Duan L. X., London W. T. Hepatitis B × antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene. 8:1993;1109-1117.
33. Greenblatt M. S., Feitelson M. A., Zhu M., Bennett W. P., Welsh J. A., Jones R., Borkowski A., Harris C. C. Integrity of p53 in hepatitis B × antigen-positive and -negative hepatocellular carcinomas. Cancer Res. 57:1997;426-432.
34. Charlotte F., L'Hermine A., Martin N., Geleyn Y., Nollet M., Gaulard P., Zafrani E. S. Immunohistochemical detection of bcl-2 protein in normal and pathological human liver. Am. J. Pathol. 144:1994;460-465.
35. Soini Y., Virkajärvi N., Lehto V. P., Pääkkö P. Hepatocellular carcinoma with high proliferation index and a low degree of apoptosis and necrosis are associated with a shortened survival. Br. J. Cancer. 73:1996;1025-1030.
36. Terada T., Nakanuma Y. Expression of apoptosis, proliferating cell nuclear antigen, and apoptosis-related antigens (bcl-2, c-myc, fas, lewis (y) and p53) in human cholangiocarcinoma and hepatocellular carcinomas. Pathol. Int. 46:1996;764-770.
37. Nakopoulou L., Stefanaki K., Vourlakou C., Manolaki N., Michalopoulos G. BCL-2 protein expression in acute and chronic hepatitis, cirrhosis and hepatocellular carcinoma. Pathol. Res. Pract. 195:1999;19-24.
38. Borner M. M., Brousset P., Pfanner-Meyer B., Bacchi M., Volanthen S., Hotz M. A., Altermatt H. J., Schlaifer D., Reed J. C., Betticher D. C. Expression of apoptosis regulatory proteins of the bcl-2 family and p53 in primary resected non-small-cell lung cancer. Br. J. of Cancer. 79:1999;952-958.
39. Wood D. E., Thomas A., Devi L. A., Berman Y., Beavis R. C., Reed J. C., Newcomb E. W. Bax cleavage is mediated by calpain during drug-induced apoptosis. Oncogene. 17:1998;1069-1078.
40. Packham G. Mutation of BCL-2 family proteins in cancer. Apoptosis. 3:1998;75-82.
41. Simms L. A., Radford-Smith G., Biden K. G., Buttenshaw R., Cumming M., Jass J. R., Young J., Meltzer S. J., Leggett B. A. Reciprocal relationship between the tumor suppressors p53 and bax in primary colorectal cancers. Oncogene. 17:1998;2003-2008.
42. Boise L. H., Gonzalez-Garcia M., Postema C. E., Ding L., Lindsten T., Turka L. A., Mao X., Nunez G., Thompson C. B. Bcl-X, a Bcl-2 related gene that functions as a dominant regulator of apoptotic cell death. Cell. 74:1993;597-608.
43. Oltvai Z. N., Milliman C. L., Korsmeyer S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell. 74:1993;609-619.
44. Reed J. C. Double identity for proteins of the Bcl-2 family. Nature (London). 387:1997;773-776.
45. Gross A., McDonnell J. M., Korsmeyer S. J. Bcl-2 family members and the mitochondria in apoptosis. Genes Dev. 13:1999;1899-1911.
46. Gross A., Jockel J., Wei M. C., Korsmeyer S. J. Enforced dimerization of bax results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J. 17:1998;3878-3885.
47. Tan Y. J., Beerheide W., Ting A. T. Biophysical characterization of the oligomeric state of bax and its complex formation with bcl-xl. Biochem. Biophys. Res. Commun. 255:1999;334-339.
48. Bargou R. C., Daniel P. T., Mapara M. Y., Bommert K., Wagener C., Kallinich B., Royer H. D., Dörken B. Expression of the bcl-2 gene family in normal and malignant breast tissue: Low bax-α expression in tumor cells correlates with resistance toward apoptosis. Int. J. Cancer. 60:1995;854-859.
49. Krajewski S., Blomqvist C., Franssila K., Krajewska M., Wasenius V-M., Niskanen E., Nordling S., Reed J. C. Reduced expression of pro-apoptotic gene bax is associated with poor response rates to chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 55:1995;4471-4478.
50. McCurach M. E., Connor T. M. F., Knudson C. M., Korsmeyer S. J., Lowe S. W. Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc. Natl. Acad. Sci. USA. 94:1997;2345-2349.
51. Tai Y. T., Lee S., Niloff E., Weisman C., Strobel T., Cannistra S. A. Bax protein expression and clinical outcome in epithelial ovarian cancer. J. Clin. Oncol. 8:1998;2583-2590.
52. Ito T., Fujieda S., Tsuzuki H., Sunaga H., Fan G. K., Sugimoto C., Fukuda M., Saito H. Decreased expression of bax is correlated with poor prognosis in oral and oropharyngeal carcinoma. Cancer Lett. 140:1999;81-91.
53. Sturm I., Köhne C. H., Wolff G., Petrowsky H., Hillebrand T., Hauptmann S., Lorenz M., Dörken B., Daniel P. T. Analysis of the p53/bax pathway in colorectal cancer: Low bax is a negative prognostic factor in patients with resected liver metastases. J. Clin. Oncol. 5:1999;1364-1374.